$-0.74 EPS Expected for Seres Therapeutics, Inc. (MCRB)

April 21, 2018 - By reb123z

Seres Therapeutics, Inc. (NASDAQ:MCRB) Logo

Analysts expect Seres Therapeutics, Inc. (NASDAQ:MCRB) to report $-0.74 EPS on May, 3.They anticipate $0.11 EPS change or 17.46 % from last quarter’s $-0.63 EPS. After having $-0.71 EPS previously, Seres Therapeutics, Inc.’s analysts see 4.23 % EPS growth. The stock decreased 2.15% or $0.17 during the last trading session, reaching $7.73. About 72,169 shares traded. Seres Therapeutics, Inc. (NASDAQ:MCRB) has declined 31.05% since April 21, 2017 and is downtrending. It has underperformed by 42.60% the S&P500.

Seres Therapeutics, Inc. (NASDAQ:MCRB) Ratings Coverage

Among 2 analysts covering Seres Therapeutics (NASDAQ:MCRB), 2 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Seres Therapeutics had 4 analyst reports since November 8, 2017 according to SRatingsIntel. The rating was maintained by Oppenheimer on Thursday, January 11 with “Buy”. Cantor Fitzgerald maintained it with “Buy” rating and $16.0 target in Thursday, March 8 report. The stock has “Buy” rating by Oppenheimer on Tuesday, March 20. As per Wednesday, November 8, the company rating was maintained by Cantor Fitzgerald.

Seres Therapeutics, Inc., a microbiome therapeutics platform company, engages in developing biological drugs designed to restore health by repairing the function of a dysbiotic microbiome. The company has market cap of $314.21 million. The Company’s lead product candidate is SER-109, a bacterial spore ecology, which has completed Phase II clinical study to treat multiply recurrent Clostridium difficile infection . It currently has negative earnings. The firm also develops SER-287 that is in Phase Ib clinical study in patients with mild-to-moderate ulcerative colitis; and SER-262, a synthetic microbiome therapeutic candidate, which is in Phase Ib study in patients with primary CDI.

Seres Therapeutics, Inc. (NASDAQ:MCRB) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.